PipelineReview.com8h
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough ...
PipelineReview.com8h
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
SAN FRANCISCO, CA, USA I7, 2025 I GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing ...
PipelineReview.com8h
Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial
I Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an ...
PipelineReview.com8h
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
AUSTIN, TX, USA and HAMILTON, Canada and SAN DIEGO, CA, USA I7, 2025 I Triumvira Immunologics, a clinical-stage company ...
PipelineReview.com1d
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...
PipelineReview.com1d
Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, China I January 26, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its ...
PipelineReview.com1d
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
LAUSANNE, Switzerland I7, 2025 I AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic ...
PipelineReview.com5d
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a ...
PipelineReview.com3d
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting
HOUSTON, TX, USA I4, 2025 I ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to ...
PipelineReview.com6d
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination ...
PipelineReview.com5d
Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology ...
PipelineReview.com4d
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
The U.S. Food and Drug Administration (FDA) has granted andecaliximab a Rare Pediatric Disease Designation (RPDD) for the treatment of FOP. An RPDD designation is granted to potential treatments for ...